Dermatologic Applications of Photodynamic Therapy
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs medical necessity and coverage criteria for photodynamic therapy used for dermatologic conditions (primarily actinic keratoses, select basal cell carcinomas, and Bowen's disease) for Blue Cross Blue Shield of North Carolina members and informs provider billing and documentation expectations.
No material clinical or coverage changes in this revision.
Coverage Criteria — When PDT Is Covered or Not Covered
When Dermatologic Applications of Photodynamic Therapy is covered
Covered when ALL of the following are met for specified conditions
Supported by policy statement and evidence summaries identifying face and scalp non-hyperkeratotic AKs as primary covered indications.
Specific lesion-count threshold added to 'When Covered' in policy history (02/11/20).
Coverage limited to situations where surgery and radiation are contraindicated per policy statement.
Coverage limited to cases with contraindication to surgery and radiation per policy statement.
When Dermatologic Applications of Photodynamic Therapy is not covered
Not covered / investigational conditions
Policy and guidelines state evidence is insufficient; RCTs and meta-analyses do not demonstrate consistent benefit for these conditions.
Explicitly designated as not medically necessary in policy statements.
Policy explicitly restricts covered anatomic locations.
Policy sets a minimum lesion count for upper extremity coverage (3 or fewer not covered).
Covered and conditional indications
Covered or appropriate uses described in policy history and converted corporate policy
Identified consistently across policy implementation and conversion notes as the primary covered indication.
Policy history repeatedly states that surgical/radiation contraindication is required for coverage of these conditions.
Specific lesion-count threshold was recorded in the 02/11/20 update to the policy history.
Investigational / Not Medically Necessary
Uses considered investigational or not medically necessary
Policy implementation notes and 'When Not Covered' section list these applications as investigational.
Policy explicitly lists cosmetic uses as not medically necessary.
Policy specifies anatomic restriction with an exception for >=4 upper extremity lesions added in policy updates.
Photodynamic therapy (PDT) is not indicated for procedures performed solely for aesthetic purposes. PDT for skin rejuvenation, hair removal, or other cosmetic indications is considered not medically necessary and is therefore outside the scope of covered dermatologic uses in this policy. Providers should verify that the reason for treatment is a covered medical diagnosis before proceeding with PDT to avoid potential claim denials.
Photodynamic therapy as a technique of skin rejuvenation, hair removal, or other cosmetic indications is explicitly designated not medically necessary. Documentation should clearly demonstrate a medically appropriate indication; procedures performed for cosmetic benefit alone are subject to denial.
PDT is not recommended for other dermatologic applications where evidence is insufficient or inconsistent. Examples explicitly listed in the policy include acne vulgaris, non-superficial basal cell carcinomas, hidradenitis suppurativa, and mycoses. Treatments for these conditions are considered investigational and are not supported as medically necessary indications by this policy.
This policy reaffirms that PDT for cosmetic indications is not medically necessary. Requests or claims submitted for cosmetic uses (including skin rejuvenation and hair removal) should be reviewed against this exclusion and may be denied if the record shows a solely cosmetic intent.
Photodynamic therapy is considered not medically necessary for treatment of non-hyperkeratotic actinic keratoses located outside the face and scalp (for example, the trunk and lower extremities), except where a specific policy exception applies. The policy history further clarifies that an exception exists for the upper extremities when there are ≥4 lesions; conversely, PDT is not medically necessary for ≤3 non-hyperkeratotic AKs on the upper extremities.
Billing and Procedure Codes
Provider Responsibilities, Authorization, and Documentation
Code listing in policy — PA and reimbursement implication
Applicable service codes are listed in the policy's Billing/Coding section (96567, 96573, 96574, J7308, J7309, J7345); inclusion of a code does not guarantee reimbursement and providers must follow the plan's prior authorization processes and administrative policies for reimbursement determinations.
Verify member benefits and plan design before applying policy
Member benefits and plan design determine coverage applicability; review the Member's Benefit Booklet or benefit language for the individual before applying policy coverage criteria.
- Member benefits may vary by benefit design; confirm benefit availability in the Member's Benefit Booklet prior to applying this medical policy
Provide complete medical records when requested
Providers must be prepared to submit complete clinical records when BCBSNC requests documentation for medical necessity determinations; letters alone are not sufficient unless they include all required clinical details.
- BCBSNC may request medical records for determination of medical necessity
- Letters of support/explanation are not sufficient unless all specific information needed for the determination is included
Use current CPT/HCPCS codes from the policy
Use the current, updated CPT/HCPCS codes listed in the policy's Billing/Coding section when billing for PDT (examples added in policy history include J7309, J7345, 96573, 96574); ensure coding aligns with the most recent policy and payer requirements.
Supplying requested records is required to avoid denial
Failure to supply requested medical records or required clinical detail may result in denial of a medical necessity determination; documentation should include the specific clinical information requested by BCBSNC.
- Failure to supply medical records may lead to denial of medical necessity determination
- Include the specific clinical information requested to support medical necessity
Risk of denial for cosmetic or out-of-scope indications
PDT performed for cosmetic indications or for non-covered anatomic locations (for example, non-hyperkeratotic AKs outside the face and scalp except as noted for multiple upper-extremity lesions) is considered not medically necessary and may be denied.
- Photodynamic therapy for skin rejuvenation, hair removal, or other cosmetic indications is considered not medically necessary
- PDT is not medically necessary for non-hyperkeratotic AKs in locations other than the face and scalp (with limited exception for ≥4 upper-extremity lesions)
Background on Photodynamic Therapy
Photodynamic therapy uses a topically or systemically administered photosensitizer (commonly topical 5-aminolevulinic acid [5-ALA] or methyl aminolevulinate) that is preferentially taken up and metabolized by dysplastic or neoplastic skin cells to porphyrin intermediates. When exposed to an appropriate light source at the photosensitizer’s absorption wavelengths, these porphyrins produce reactive oxygen species that cause localized cellular damage and destruction of abnormal tissue. Adverse effects reported in clinical studies include erythema, burning, and pain, with healing typically occurring over approximately 10–14 days. The policy’s description and history note these mechanisms and reference specific photosensitizing agents and device updates over time.
Key Definitions and Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.